- Home
- KNSA vs QGEN Comparison
KNSA vs QGEN Comparison
Compare KNSA & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNSA | QGEN |
|---|---|---|
| Founded | 2015 | 1986 |
| Country | United Kingdom | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 9.0B |
| IPO Year | 2018 | 1998 |
Fundamental Metrics
Financial Performance| Metric | KNSA | QGEN |
|---|---|---|
| Price | $94.47 | $50.34 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 12 |
| Target Price | ★ $109.43 | $49.02 |
| AVG Volume (30 Days) | 925.9K | ★ 5.4M |
| Earning Date | 10-27-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 5.43% |
| EPS Growth | ★ 225.00 | N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $677,564,000.00 | N/A |
| Revenue This Year | $54.96 | $2.18 |
| Revenue Next Year | $24.16 | $5.03 |
| P/E Ratio | $84.32 | ★ $24.01 |
| Revenue Growth | ★ 60.09 | N/A |
| 52 Week Low | $37.02 | $32.53 |
| 52 Week High | $98.48 | $57.82 |
Technical Indicators
Market Signals| Indicator | KNSA | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 60.03 | 67.73 |
| Support Level | $72.76 | $49.72 |
| Resistance Level | $98.48 | $50.82 |
| Average True Range (ATR) | 5.49 | 0.77 |
| MACD | 0.78 | -0.05 |
| Stochastic Oscillator | 84.57 | 84.83 |
Price Performance
Historical ComparisonAbout KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).